Literature DB >> 23457055

Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway.

Dana Holzinger1, Christa Flechtenmacher, Nataly Henfling, Ines Kaden, Niels Grabe, Bernd Lahrmann, Markus Schmitt, Jochen Hess, Michael Pawlita, Franz X Bosch.   

Abstract

Viral oncogene RNA expression is regarded as reliable biomarker to identify oropharyngeal squamous cell carcinomas (OPSCC) with active HPV16 involvement. This study addressed whether the expression profile of the cellular proteins p16(INK4a), pRb, Cyclin D1 and p53 provide surrogate marker combinations that identify OPSCC with active HPV16 in situations where only formalin-fixed biopsies are available. Protein expression was analyzed by immunohistochemistry on tissue microarrays created from 188 OPSCC of which the HPV16 DNA and RNA status had been established previously from snap-frozen biopsies. Associations of single markers and of marker combinations with HPV16 DNA, viral RNA expression patterns and overall survival as primary end point were evaluated by statistical analysis. Most tumors with active HPV16 involvement (RNA(+) group; n = 40) showed a specific protein pattern, that is, high p16(INK4a) (80%), low pRb (85%), low Cyclin D1 (95%) and normal p53 (73%). This pattern was significantly different from the pattern observed in HPV DNA-negative tumors (HPV(-) group) and in HPV16 DNA-positive tumors lacking viral RNA expression patterns (RNA(-) group). The combination of high p16(INK4a) and low pRb levels was distinctly superior to p16(INK4a) alone; it was strongly associated with RNA(+) tumors (OR 41.4, 95%CI 10.7-162.5), with improved survival (HR 0.37, 95%CI 0.2-0.8) and had best predictive values (78% sensitivity, 93% specificity, 78% PPV, 93% NPV). In conclusion, if only formalin-fixed biopsy material is available, the marker combination high p16(INK4a) /low pRb is well suited to identify OPSCC with biologically active HPV16 which represent a distinct OPSCC entity with improved prognosis.
Copyright © 2013 UICC.

Entities:  

Keywords:  Cyclin D1; active HPV infection; head and neck squamous cell carcinoma; human papilloma virus; immunohistochemistry; oropharynx; p16INK4a; p53; pRb; tissue microarray

Mesh:

Substances:

Year:  2013        PMID: 23457055     DOI: 10.1002/ijc.28142

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  p16 overexpression in high-grade neuroendocrine carcinomas of the head and neck: potential diagnostic pitfall with HPV-related carcinomas.

Authors:  Llucia Alos; Sofia Hakim; Ana-Belen Larque; Jorge de la Oliva; Leonardo Rodriguez-Carunchio; Miguel Caballero; Alfons Nadal; Carles Marti; Nuria Guimera; Maria-Teresa Fernandez-Figueras; Wim Quint; Jaume Ordi
Journal:  Virchows Arch       Date:  2016-07-08       Impact factor: 4.064

2.  High-risk HPV types and head and neck cancer.

Authors:  Dominique S Michaud; Scott M Langevin; Melissa Eliot; Heather H Nelson; Michael Pawlita; Michael D McClean; Karl T Kelsey
Journal:  Int J Cancer       Date:  2014-03-07       Impact factor: 7.396

3.  Human papillomavirus status and gene expression profiles of oropharyngeal and oral cancers from European American and African American patients.

Authors:  Swati Tomar; Christian A Graves; Diego Altomare; Sangeeta Kowli; Susannah Kassler; Natalie Sutkowski; M Boyd Gillespie; Kim E Creek; Lucia Pirisi
Journal:  Head Neck       Date:  2015-06-15       Impact factor: 3.147

4.  Biological relevance of human papillomaviruses in vulvar cancer.

Authors:  Gordana Halec; Laia Alemany; Beatriz Quiros; Omar Clavero; Daniela Höfler; Maria Alejo; Wim Quint; Michael Pawlita; Francesc X Bosch; Silvia de Sanjose
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

5.  Pathway Analysis using Gene-expression Profiles of HPV-positive and HPV-negative Oropharyngeal Cancer Patients in a Hispanic Population: Methodological Procedures.

Authors:  Erick Suárez; Lorena González; Carlos Pérez-Mitchell; Ana P Ortiz; Maricarmen Ramírez-Sola; Jaime Acosta; Raúl D Bernabe-Dones; Carlos González-Aquino; Ingrid Montes-Rodríguez; Carmen L Cadilla
Journal:  P R Health Sci J       Date:  2016-03       Impact factor: 0.705

Review 6.  P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects.

Authors:  Hongzhi Wang; Rui Sun; Hui Lin; Wei-Han Hu
Journal:  Cancer Sci       Date:  2013-11-08       Impact factor: 6.716

7.  Mucosal alpha-papillomaviruses are not associated with esophageal squamous cell carcinomas: Lack of mechanistic evidence from South Africa, China and Iran and from a world-wide meta-analysis.

Authors:  Gordana Halec; Markus Schmitt; Sam Egger; Christian C Abnet; Chantal Babb; Sanford M Dawsey; Christa Flechtenmacher; Tarik Gheit; Martin Hale; Dana Holzinger; Reza Malekzadeh; Philip R Taylor; Massimo Tommasino; Margaret I Urban; Tim Waterboer; Michael Pawlita; Freddy Sitas
Journal:  Int J Cancer       Date:  2016-01-21       Impact factor: 7.396

8.  Human papilloma virus and survival of oropharyngeal cancer patients treated with surgery and adjuvant radiotherapy.

Authors:  Martina A Broglie; Alex Soltermann; Sarah R Haile; Gerhard F Huber; Sandro J Stoeckli
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-01       Impact factor: 2.503

9.  Combined P16 and human papillomavirus testing predicts head and neck cancer survival.

Authors:  Christian R Salazar; Nicole Anayannis; Richard V Smith; Yanhua Wang; Missak Haigentz; Madhur Garg; Bradley A Schiff; Nicole Kawachi; Jordan Elman; Thomas J Belbin; Michael B Prystowsky; Robert D Burk; Nicolas F Schlecht
Journal:  Int J Cancer       Date:  2014-04-17       Impact factor: 7.396

10.  Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

Authors:  Amanda Psyrri; Ju-Whei Lee; Eirini Pectasides; Maria Vassilakopoulou; Efstratios K Kosmidis; Barbara A Burtness; David L Rimm; Harold J Wanebo; Arlene A Forastiere
Journal:  Clin Cancer Res       Date:  2014-04-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.